Maravai Lifesciences Holdings, Inc. Stock Price, News & Analysis

Maravai LifeSciences reported a remarkable revenue increase of 364.3% year-over-year, totaling $217.8 million for Q2 2021. Net income reached $134.3 million, significantly up from $1.4 million in the prior year. The company raised its full-year revenue guidance to $745 million - $770 million. Key growth drivers included a 532.8% increase in Nucleic Acid Production revenue, alongside the divestiture of its Protein Detection segment for $124 million. Expansion plans for facilities are underway to enhance production capabilities in response to rising demand.

TriLink BioTechnologies has enabled the Chula Vaccine Research Center in Thailand to advance its mRNA Covid-19 vaccine into a First in Human phase 1 clinical trial. This initiative aims to enhance vaccine access in economically developing countries, providing a crucial response to the ongoing pandemic. TriLink will support the manufacturing through its proprietary CleanCap technology, facilitating the production of the vaccine's first clinical batch. This partnership also aims to prepare for future pandemics and new variants.

Maravai LifeSciences (NASDAQ: MRVI) will announce its second quarter 2021 financial results after market close on August 10, 2021. A conference call is scheduled for the same day at 2:00 PM PT/5:00 PM ET. Interested participants can join by dialing (833) 693-0536 or (661) 407-1576, using conference ID 2296674. The call will be accessible for replay for 72 hours and will also be available via webcast on Maravai's investor website.

Maravai is a leader in life sciences, providing vital products for drug development, diagnostics, and vaccine research.

Maravai LifeSciences (NASDAQ: MRVI) will participate in several upcoming virtual investor conferences in June 2021. CFO Kevin Herde will speak at the William Blair Annual Growth Stock Conference on June 1, followed by another fireside chat at the Jefferies Healthcare Conference on June 2. CEO Carl Hull will present at the Goldman Sachs Healthcare Conference on June 10. Webcasts of these events will be available on the company's investor relations website, along with archived versions after each event.

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) reported a 190.7% increase in Q1 2021 revenue, reaching $148.2 million. Key drivers included a 306.5% surge in Nucleic Acid Production, totaling $123.9 million, fueled by strong demand for COVID-19 vaccine components. Biologics Safety Testing and Protein Detection also saw growth of 23.5% and 7.0% respectively. The company updated its 2021 revenue guidance to between $680 million and $720 million, reflecting anticipated growth of 139.4% to 153.5% over the year.

Maravai LifeSciences, Inc. (NASDAQ: MRVI) announced its participation in two upcoming virtual investor conferences in May 2021. CFO Kevin Herde will speak at the Bank of America Global Healthcare Conference on May 12 at 10:15 a.m. PT, while CEO Carl Hull will present at the UBS Global Healthcare Conference on May 25 at 2:00 p.m. PT. Live webcasts will be available on the Maravai investor relations website, with archived versions accessible shortly after each event. Maravai is known for its critical life science products supporting drug therapies, diagnostics, and research.

Maravai LifeSciences, Inc. (NASDAQ: MRVI) will announce its Q1 2021 financial results on May 10, 2021, after market close. A conference call is scheduled for the same day at 2:00 PM PT/5:00 PM ET. Participants can join by calling (833) 693-0536 or (661) 407-1576 using conference ID 4090862. An audio replay will be available for 72 hours after the call. Maravai is a leading provider of life science reagents and services, supporting drug therapy and vaccine development.

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) announced the closing of a public offering of 20.7 million shares of its Class A common stock by certain selling stockholders at $31.25 per share. This offering included the full exercise of underwriters' option for an additional 2.7 million shares. Notably, Maravai did not receive any proceeds from this sale. Major banks including Morgan Stanley and Jefferies served as joint book-running managers for the offering.

Maravai LifeSciences Holdings, Inc. (MRVI) announced an upsized public offering of 18,000,000 shares of Class A common stock at a price of $31.25 per share. This offering, increased by 3,000,000 shares from previous announcements, includes a 30-day option for underwriters to purchase an additional 2,700,000 shares. The offering is set to close on April 12, 2021. Notably, Maravai will not receive proceeds from this sale, which is managed by firms including Morgan Stanley, Jefferies, and Goldman Sachs.